期刊文献+

托伐普坦片在高龄老年人中的有效性及安全性研究 被引量:6

Observation of the efficacy and safety of tolvaptan in very old people
下载PDF
导出
摘要 目的观察托伐普坦片在高龄老年人中使用的有效性及安全性。方法收集并比较用药前后患者血压、尿量、水肿情况,除托伐普坦片外的其他利尿剂使用情况,以及血清电解质、谷丙转氨酶、肾小球滤过率、血浆渗透压的改变。结果用药前后观察到尿量的轻度增加,除托伐普坦片以外的其他利尿剂剂量减少,血清钠离子浓度及血浆渗透压明显增加,谷丙转氨酶没有明显改变、肾小球滤过率轻度下降。结论在高龄老年人中,使用托伐普坦片可以纠正低钠血症,减少传统利尿剂的用药剂量;托伐普坦片在高龄老年人中应用基本安全,但需要更严密的监测血钠水平及肾功能。 Objective To observe the efficacy and safety of tolvaptan in very old people. Method The blood pressure,urine volume,edema,doses of diuretics,serum electrolyte,alanine aminotransferase,glomerular filtration rate and plasma osmotic pressure were observed before and after treatment. Result We observed a slight increase in urine volume and reduction of doses of diuretic. Serum sodium and plasma osmotic pressure increased significantly after treatment. There is no change of alanine transaminase and mild decline in glomerular filtration rate. Conclusion Tolvaptan can be used to treat hyponatremia and oliguria;It is safe in elderly,but require pay close attention to serum sodium levels and renal function.
机构地区 北京医院
出处 《中国临床医生杂志》 2016年第3期32-35,共4页 Chinese Journal For Clinicians
关键词 托伐普坦片 高龄老年人 高钠血症 Tolvaptan Elderly people Hypernatronemia
  • 相关文献

参考文献11

  • 1中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. 被引量:4669
  • 2Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-termclinicaleffects of tolvaptan, an oral vasopressin antagonist, in patientshospi- talized for heart failure:the Everest Clinical StatusTrials [ J ]. JAMA, 2007(297) :1332-1343.
  • 3Matsuzaki M, Hori M, Izumi T, et al. Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase 11I, randomized, double-blind, placebocontrolled study ( quest study) [J]. Cardiovasc Drug Ther,2011 (25) :$33-45.
  • 4Kinugawa K, Inomata T, Sato N, et al. Effectiveness and adverse e- veins of tolvaptan in octogenarians with heart failure[J]. Int Heart J, 2015,56(2) :137-146.
  • 5Kinugawa K,Sato N,Inomata T,et 81. Efficacy and Safety of Tolvap- tan in Heart Failure Patients With Volume Overload [ J ]. Circulation Journal,2014 (78) :844-852.
  • 6Miller M, Morley JE, Rubenstein LZ. Hyponatremia in a nursing home population[J].J AmGeriatr Soc, 1995 (43) :1410-1413.
  • 7Hoyle GE, Chua M, Soiza RL. Prevalence of hyponatremia in elderlypatients[J]. J Am Geriatr Soe,2006(54) :1473.
  • 8Walkar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild,moderate and severe hyponatremia[ J ]. Am J Med,2009 ( 122 ) : 679 -686.
  • 9Sehrier RW, Gross P, Gheorghiode M, et al. Tolvaptan, a selective o- ral vasopressin V2-reeeptor antagonist, for hyponatremia [ J ]. N Engl J Med,2006(355) :2099-2112.
  • 10Goce S, Raymond V, Bruno A, et al. Clinical practice guideline on di- agnosis and treatment of hyponatraemia [ J ]. Intensive Care Med, 2014,40(3 ) :320-331.

二级参考文献5

共引文献4668

同被引文献37

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部